• Zai Lab’s Phase 1b/2 trial showed durable tumor responses to zocilurtatug pelitecan in previously treated advanced extrapulmonary neuroendocrine carcinomas.
• Updated results will be presented November 6, 2026, at the North American Neuroendocrine Tumor Society symposium in Las Vegas.
• Treatment showed a manageable safety profile, with few treatment-related discontinuations and no treatment-related deaths.
• The company plans to pursue potential accelerated approval based on its single-arm expansion study, with topline data expected in 2027.
• A global Phase 3 trial evaluating the drug as first-line maintenance monotherapy is expected to begin in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050900BIZWIRE_USPR_____20261105_BW430679) on November 05, 2026, and is solely responsible for the information contained therein.